Novogen (NASDAQ:KZIA) Given “Buy” Rating at BTIG Research

Novogen (NASDAQ:KZIA)‘s stock had its “buy” rating restated by investment analysts at BTIG Research in a report issued on Wednesday,Benzinga reports. They currently have a $34.00 price objective on the stock. BTIG Research’s price target would indicate a potential upside of 147.40% from the company’s previous close.

Other research analysts have also recently issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a research note on Tuesday, April 21st. Lake Street Capital assumed coverage on shares of Novogen in a research note on Thursday, June 11th. They issued a “buy” rating and a $32.00 price target for the company. Finally, Laidlaw began coverage on shares of Novogen in a research note on Wednesday, April 15th. They set a “buy” rating and a $25.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $25.80.

Novogen Trading Up 2.0%

NASDAQ:KZIA traded up $0.27 during mid-day trading on Wednesday, hitting $13.74. The stock had a trading volume of 66,326 shares, compared to its average volume of 211,654. The company has a 50 day simple moving average of $13.21 and a 200-day simple moving average of $9.69. Novogen has a 52 week low of $4.86 and a 52 week high of $17.40.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.